USA-based Genentech refused to comment on its possible merger with Swiss drug major Roche in its third-quarter conference call, leaving analysts perplexed, according to a blog on the Seeking Alpha web site. According to the report by analyst Mike Huckman on the investors' forum, the firm's chief financial officer, David Ebersman, said: "we understand your frustration, but we've been advised not to say anything." Cowen and Co's Eric Schmidt still believes, however, that a deal for over $90 per share is still inevitable, though he notes his frustration with Genentech's secrecy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Genentech refuses to comment on Roche merger
USA-based Genentech refused to comment on its possible merger with Swiss drug major Roche in its third-quarter conference call, leaving analysts perplexed, according to a blog on the Seeking Alpha web site. According to the report by analyst Mike Huckman on the investors' forum, the firm's chief financial officer, David Ebersman, said: "we understand your frustration, but we've been advised not to say anything." Cowen and Co's Eric Schmidt still believes, however, that a deal for over $90 per share is still inevitable, though he notes his frustration with Genentech's secrecy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
Become a subscriber
£820
Or £77 per month
Chairman, Sanofi Aventis UK
Company News Directory
Companies featured in this story
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze